Current Students Sample Clauses

Current Students. Current students who are pregnant, sustain an injury, have surgery, develop mental illness, substance abuse, or a chronic health illness and/or any other condition requiring medical (including pharmaceutical), psychiatric or psychological treatment (including pharmaceutical), must notify their clinical instructor and make an appointment with the Director of Nursing as soon as the student becomes aware of such condition (within 2 business days). At this meeting, the student must state their condition and provide his/her physician’s name and address to the Director of Nursing to facilitate sending a Release Request Form. Refer to Appendix: Medical Release. This form describes the activities required in clinical. It requests the physician to return (via student or fax) the written release form to the Director for the student to resume those activities, if appropriate, and to list any limitations. (See: Impaired Student Nurse) The student may not be allowed to attend clinical and/or class until the physician’s release form is received. The student is responsible for obtaining the medical release form before returning to clinical and/or class. If, in the instructor’s judgment, stated limitations would pose a safety risk to clients, staff, and/or the student, or otherwise prevent the student from meeting course objectives, the student will be required to drop the course (both clinical and theory components). Filing of a formal student petition or grievance shall not impede this process nor shall it allow the student to continue in the course if the instructor decides otherwise. Failure to inform the Director of Nursing of changes in student’s health status within 2 business days may result in disqualification from the program. DRESS CODE
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Current Students. (a) Credits earned by students enrolled at the Indianapolis campus prior to the Realignment Effective Date will be fully transferable to IU or Purdue, as applicable, based upon which school, college or division within an IU Realigned Academic Unit or Purdue Realigned Academic Unit such student enrolls.
Sample 1Sample 2
Current Students. The University is aware that changes being discussed at the moment with regards to tuition fees and funding will create anxiety within the existing student population. In order to minimise such anxieties, information will be provided to our current student cohort via the internal Virtual Learning Environment, Studyspace, and the Kingston University Student’s Union web pages. FAQs will be compiled for distribution amongst colleagues, both academic and professional, in order that they may feel suitably equipped to answer any queries that arise from the current student population. Table 5 - Milestones and targets Table 5a - Statistical milestones and targets relating to your applicants, entrants or student body (e.g. HESA, UCAS or internal targets) Please select milestone/target type from the drop down menu Description (500 characters maximum) Baseline Baseline year data Yearly milestones/targets (numeric where possible, however you may use text) 2012-13 2013-14 2014-15 2015-16 2016-17 Commentary on your milestones/targets or textual description where numerical description is not appropriate (500 characters maximium) Non continuation: All (HESA Table T3a) Increase the first year continuation rate of students with BTEC, Access or foundation year entry qualifications by 0.5% per year for the first three years of the access agreement, then maintain it over the the remainder of the access agreement 2008/09 to 2009/10 0.852 0.857 0.862 0.867 0.867 0.867 Data underlying the Performance Indicator from HESA Table T3a to be used to measure and monitor Other (please give details in the next column) Maintain the proportion students with BTEC, Access or foundation year entry qualifications acheiving of first and upper second class honours degrees over the course of the access agreement 2009/10 0.639 0.639 0.639 0.639 0.639 0.639 HESA student return data to be used to measure and monitor Other (please give details in the next column) Increase the proportion of students with BTEC, Access or foundation year entry qualifications obtaining graduate employment within six months of graduation by 0.5% each year over the course of the access agreement. Graduating in 2008/09 0.791 0.796 0.801 0.806 0.811 0.816 Data underlying the Performance Indicator from HESA Table E to be used to measure and monitor. Data for each yearly milestone available from June the previous year. NS-SEC (location adjusted) (HESA Table T1b) To maintain the proportion of entrants from low NS-SEC groups abov...
Sample 1
Current Students. (a) Credits earned by students enrolled at the Fort Xxxxx Campus prior to the Realignment Effective Date shall be fully transferable to IU or Purdue, as applicable, based upon which school, college or division within an Indiana Academic Mission or Purdue Academic Mission such student enrolls.
Sample 1
Current Students. (defined as any student who has attended AU for at least one semester)
Sample 1
Current Students. (defined as any student who has attended AU or GWC for at least one semester)
Sample 1
Current Students. 20. The College will inform all current undergraduate students of the changes in the fee structure for students entering the College in 2008 and explain that these will not affect students continuing on their current programme of study, with regard to their fee liability. As a result, they will be ineligible for assistance from the Bursary Scheme. However, from 2008 students will not need to pay fees up-front, but can do so after graduation. Again, the information will reiterate the financial support that will continue to be made available to these students. This information will be placed on the College website and will also be published in the College student newspaper.
Sample 1
AutoNDA by SimpleDocs
Current Students. Not living on campus ● Current students who reside off campus will be assigned pending availability of space.
Sample 1

Related to Current Students

  • Students Payments which a student or business apprentice who is or was immediately before visiting a Contracting State a resident of the other Contracting State and who is present in the first-mentioned State solely for the purpose of his education or training receives for the purpose of his maintenance, education or training shall not be taxed in that State, provided that such payments arise from sources outside that State.

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

  • MEDICALLY FRAGILE STUDENTS 1. If a teacher will be providing instructional or other services to a medically fragile student, the teacher or another adult who will be present when the instruction or other services are being provided will be advised of the steps to be taken in the event an emergency arises relating to the student's medical condition.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Medicaid Program Parties (applicable to any Party providing services and supports paid for under Vermont’s Medicaid program and Vermont’s Global Commitment to Health Waiver):

  • Training Courses 16.3.1 Training courses will be as described in the Seller’s customer services catalog (the “Seller’s Customer Services Catalog”). The Seller’s Customer Services Catalog also sets forth the minimum and maximum number of trainees per course. All training requests or training course changes made outside of the scope of the Training Conference will be submitted by the Buyer with a minimum of ***** prior notice.

  • Trials The Ship shall run the following test and trials:

  • Prosthodontics We Cover prosthodontic services as follows: • Removable complete or partial dentures, for Members 15 years of age and above, including six (6) months follow-up care; • Additional services including insertion of identification slips, repairs, relines and rebases and treatment of cleft palate; and • Interim prosthesis for Members five (5) to 15 years of age. We do not Cover implants or implant related services. Fixed bridges are not Covered unless they are required: • For replacement of a single upper anterior (central/lateral incisor or cuspid) in a patient with an otherwise full complement of natural, functional and/or restored teeth; • For cleft palate stabilization; or • Due to the presence of any neurologic or physiologic condition that would preclude the placement of a removable prosthesis, as demonstrated by medical documentation.

Time is Money Join Law Insider Premium to draft better contracts faster.